XML 27 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, PPE, Licensing and Research (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Oct. 31, 2014
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Research and Product Development            
Product development and research costs   $ 1,304,658 $ 1,261,863 $ 4,195,003 $ 4,639,617  
Investments Available for Sale            
Fair value of investments   35,028,841   35,028,841   $ 40,759,703
Gross unrealized losses   76,399   76,399    
Gross unrealized gains   35,274   35,274    
Realized gains   57   57    
Realized losses   199,758   704,752    
Research and Development            
Research and Development Expense   $ 1,304,658 $ 1,261,863 $ 4,195,003 $ 4,639,617  
Baxter Healthcare Organization            
Revenue Recognition            
Initial Payment Received $ 20,000,000